InsiderClue
← All stocks

Septerna, Inc.

SEPN Net selling
CIK 0001984086 #2087 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$76.05M
$7.40M on a plan · $5.14M straight out of an exercise
Sold at will
$63.52M
3 of 27 sales
Net
−$76.05M
−$63.52M against sales at will

By person

10 insiders · 27 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
Director
—
$63.45M (2)
−$63.45M
725,443
1.55%
$27.44M
—
Third Rock Ventures V, L.P. entity
10% owner
—
$7.40M (2) scheduled
−$7.40M
9,220,847
19.75%
$348.80M
+1,113%
Shaikhly Samira
Chief People Officer
—
$2.80M (8) scheduled
−$2.80M
793
0.0017%
$30.00K
0.0%
Bhatt Elizabeth
President and COO
—
$1.45M (7) scheduled
−$1.45M
174,209
0.3732%
$6.59M
0.0%
Long Daniel D.
SVP, Drug Discovery
—
$951.33K (8) scheduled
−$951.33K
96,412
0.2066%
$3.65M
−3.5%
Third Rock Ventures VI, L.P. entity
10% owner
—
—
—
4,211,659
9.02%
$159.31M
+33.6%
Finer Jeffrey
Chief Executive Officer
—
—
—
826,907
1.77%
$31.28M
+9.5%
Ezekowitz Alan
Director
—
—
—
117,420
0.2516%
$4.44M
+574.1%
Labrucherie Gil M
Chief Financial Officer
—
—
—
40,000
0.0857%
$1.51M
—
Klein Uwe
SVP, Biological Sciences
—
—
—
23,008
0.0493%
$870.33K
—

Individual transactions

27
Insider
Date
Role
Action
Shares
Price
Amount
Long Daniel D.
1 Sep 2026
SVP, Drug Discovery
Sold after exercise
3,333
$37.83
$126.08K
RA CAPITAL MANAGEMENT, L.P.
12 Aug 2026
Director
Sell indirect
746,500
$42.50
$31.73M
RA CAPITAL MANAGEMENT, L.P.
12 Aug 2026
Director
Sell indirect
746,500
$42.50
$31.73M
Third Rock Ventures V, L.P.
12 Aug 2026
10% owner
Sold on a plan
141
$51.08
$7.20K
Third Rock Ventures V, L.P.
12 Aug 2026
10% owner
Sold on a plan
147,059
$50.27
$7.39M
Bhatt Elizabeth
11 Aug 2026
President and COO
Sold after exercise
25,000
$44.00
$1.10M
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
2,334
$34.68
$80.94K
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
1,000
$33.98
$33.98K
Bhatt Elizabeth
15 Jul 2026
President and COO
Sold after exercise
4,000
$33.99
$135.97K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
1,233
$34.81
$42.93K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
2,100
$34.10
$71.60K
Shaikhly Samira
29 Jun 2026
Chief People Officer
Sold after exercise
2,178
$35.18
$76.62K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
7,000
$35.97
$251.78K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
8,000
$35.10
$280.80K
Shaikhly Samira
12 Jun 2026
Chief People Officer
Sold after exercise
6,250
$35.08
$219.22K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
2,889
$29.66
$85.70K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,346
$28.79
$38.76K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,700
$27.78
$47.23K
Shaikhly Samira
26 May 2026
Chief People Officer
Sold after exercise
11,798
$30.06
$354.66K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
326
$25.86
$8.43K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
1,101
$25.24
$27.79K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
2,573
$23.76
$61.12K
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
66,363
$28.14
$1.87M
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
4,090
$27.51
$112.50K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
1,800
$29.58
$53.25K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
2,200
$28.46
$62.61K
Long Daniel D.
10 Nov 2025
SVP, Drug Discovery
Sell
3,501
$18.06
$63.22K

What was left out

Form 4 filings counted 34
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 22
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 158,614
History held since 28 Oct 2024